Differential Regulation of Na-K-Cl Cotransport

描述（由申请人提供）：气道上皮NKCC 1通过供应Cl分泌到气道腔中，与基底外侧Na-K-2Cl共转运的分泌形式具有相同的特性。NKCC 1在维持纤毛周围的纤毛周液层中也具有非分泌作用，这是最佳粘膜纤毛清除所必需的。损害睫状体周围液层被认为有助于肺部疾病的病理生理学，如哮喘、支气管炎和囊性纤维化。我们以前的研究建立了蛋白激酶C-δ（PKC 4）及其与支架肌动蛋白的结合，在气道上皮NKCC 1的激活中起关键作用，包括高渗应激，低细胞内Cl和Gs偶联受体。我们鉴定了一个由NKCC 1的N末端、蛋白磷酸酶2A（PP 2A）、应激激活的丝氨酸-苏氨酸激酶SPAK和PKC 4组成的调节蛋白质组，但不了解蛋白质组如何调节NKCC 1的功能。我们还发现了NKCC 1的C末端（CT）与铜转运蛋白Murr 1（COMMD 1）的相互作用，以及Murr 1下调后高渗应激对NKCC 1活化的影响。我们还没有确定Murr 1如何调节NKCC 1。我们研究的长期目标是了解蛋白质-蛋白质相互作用如何调节NKCC 1。我们的具体目的是：1）验证PKC 4调节SPAK功能的假说。我们将使用沉默RNA将SPAK的下调与NKCC 1和PKC 4的激活相关联。我们将研究PKC 4与SPAK的结合以及PKC 4对SPAK的磷酸化和PP 2A的去磷酸化。将确定与SPAK相互作用的蛋白质的结合基序，并通过氧化足迹法建立结合热力学。2)为了验证Murr 1调节NKCC 1表面表达的假设。我们将确定a）通过使用沉默RNA下调Murr 1，Murr 1是否是NKCC 1的表面表达和功能所必需的，B）NKCC 1在基底外侧膜中的周转时间以及肌动蛋白和Murr 1对其的调节，以及c）Murr 1和CT-NKCC 1的结合基序，使用氧化足迹法和质谱法的新方法，我们将从中开发抑制肽以改变末端反应，包括蛋白质相互作用、NKCC 1活性和NKCC 1表面表达。3)验证NKCC 1磷酸化调节其活性的假设。我们将确定SPAK和PP 2A在NKCC 1磷酸化中的作用。我们计划测试编码抑制NKCC 1激活的假定磷酸化位点的肽，并计划下调关键酶，并将质量和活性损失与对NKCC 1功能的影响相关联。项目叙述：该项目是理解蛋白质相互作用在Na-K-2Cl活性调节中的重要性和突出作用的重要的第一步。从这些研究中获得的新信息将使我们朝着纠正NKCC 1功能缺陷的方向更进一步，并导致开发独特的治疗工具，以促进NKCC 1在疾病状态下的功能。更重要的是，这些研究将为预测和测试改变NKCC 1功能的药物和娱乐药物的作用奠定基础。

DESCRIPTION (provided by applicant): Airway epithelial NKCC1 shares properties with secretory forms of basolateral Na-K-2Cl cotransport by supplying Cl for secretion into the airway lumen. NKCC1 also has a non-secretory role in the maintenance of a periciliary fluid layer surrounding cilia, which are necessary for optimal mucociliary clearance. Compromising the periciliary fluid layer is thought to contribute to the pathophysiology of lung disorders, such as asthma, bronchitis, and cystic fibrosis. Our previous studies established a key role for protein kinase C-delta (PKC4) and its binding to the scaffold actin, in the activation of airway epithelial NKCC1 by multiple stimuli, including hyperosmotic stress, low intracellular Cl, and Gs coupled receptors. We identified a regulatory proteome, consisting of the N terminus of NKCC1, protein phosphatase 2A (PP2A), stress activated serine-threonine kinase SPAK and PKC4, but do not understand how the proteome regulates NKCC1 function. We also discovered the interaction of the C terminus (CT) of NKCC1 with a copper transport protein Murr1 (COMMD1) and loss of NKCC1 activation by hyperosmotic stress after downregulation of Murr1. We have yet to ascertain how Murr1 regulates NKCC1. The long term goal of our research is to understand how protein-protein interactions regulate NKCC1. We propose the following specific aims: 1) To test the hypothesis that PKC4 regulates the function of SPAK. We will correlate downregulation of SPAK, using silencing RNA, with activation of NKCC1 and of PKC4. We will investigate binding of PKC4 to SPAK and phosphorylation of SPAK by PKC4 and dephosphorylation by PP2A. Binding motifs for proteins interacting with SPAK will be determined and the thermodynamics of binding established by oxidative footprinting. 2) To test the hypothesis that Murr1 regulates NKCC1 surface expression. We will determine a) whether Murr1 is necessary for surface expression and function of NKCC1 by downregulating Murr1 using silencing RNA, b) the turnover time of NKCC1 in the basolateral membrane and its regulation by actin and Murr1 and c) binding motifs for Murr1 and CT-NKCC1, using novel methods of oxidative footprinting and mass spectrometry, from which we will develop inhibitory peptides to alter end responses, including protein interaction, NKCC1 activity, and NKCC1 surface expression. 3) To test the hypothesis that phosphorylation of NKCC1 modulates its activity. We will determine a role for SPAK and PP2A in NKCC1 phosphorylation. We plan to test peptides encoding putative phosphorylation sites for inhibition of NKCC1 activation and plan to downregulate the critical enzyme and correlate loss of mass and activity with effects on NKCC1 function. Project Narrative: This project is an important first step in understanding the importance and prominent role of protein interactions in the regulation of Na-K-2Cl activity. New information gained from these studies will take us one step further toward correcting defective NKCC1 function and lead to the development of unique therapeutic tools to promote NKCC1 function in disease states. More importantly, the studies will lay the foundation for predicting and testing the effects of drugs, both pharmaceutical and recreational, that alter NKCC1 function.